What is NON RARE IN EUROPE: Alzheimer disease?
Alzheimer disease (also called Alzheimer's disease or AD) is the most common cause of dementia, a condition where the brain gradually loses its ability to think, remember, and carry out daily tasks. It mainly affects older adults, though early-onset forms can appear before age 65. In Alzheimer disease, abnormal proteins called amyloid plaques and tau tangles build up in the brain, damaging and eventually killing nerve cells. This leads to progressive memory loss, confusion, difficulty with language, changes in mood and personality, and trouble performing familiar activities. The disease typically starts with mild forgetfulness — such as misplacing things or struggling to find the right word — and slowly worsens over years. As it progresses, people may have trouble recognizing loved ones, become disoriented in familiar places, and eventually need full-time care for basic needs like eating and bathing. While there is no cure for Alzheimer disease, the treatment landscape has expanded significantly. FDA-approved medications like cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine can help manage symptoms. Newer disease-modifying therapies such as lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques and may slow disease progression in early stages. Supportive care, cognitive stimulation, and caregiver support remain essential parts of managing the condition.
Key symptoms:
Short-term memory lossDifficulty finding the right wordsConfusion about time or placeTrouble with planning or problem-solvingMisplacing things and being unable to retrace stepsDifficulty completing familiar tasksChanges in mood or personalityWithdrawal from social activitiesPoor judgment or decision-makingGetting lost in familiar placesRepeating questions or storiesDifficulty recognizing family or friendsTrouble with reading or judging distancesAgitation, anxiety, or depressionDifficulty with eating and swallowing in late stages
- Inheritance
- Multifactorial
- Caused by a mix of several genes and environmental factors
- Age of Onset
- Late onset
- Begins later in life, typically after age 50
FDA & Trial Timeline
10 eventsOhio State University
China Medical University Hospital — NA
University of Illinois at Chicago — NA
Baycrest — NA
Johns Hopkins University — NA
University of Alabama at Birmingham — NA
Northwestern University
Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.
Treatments
Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
No FDA-approved treatments are currently listed for NON RARE IN EUROPE: Alzheimer disease.
20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
Specialists
View all specialists →Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
No specialists are currently listed for NON RARE IN EUROPE: Alzheimer disease.
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to NON RARE IN EUROPE: Alzheimer disease.
Community
No community posts yet. Be the first to share your experience with NON RARE IN EUROPE: Alzheimer disease.
Start the conversation →Latest news about NON RARE IN EUROPE: Alzheimer disease
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for NON RARE IN EUROPE: Alzheimer disease.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What stage of Alzheimer disease am I (or my loved one) in, and what can we expect in the coming months?,Am I a candidate for newer disease-modifying treatments like lecanemab, and what are the risks and benefits?,Should we pursue genetic testing, especially if there is a family history of early-onset Alzheimer disease?,What non-drug approaches can help maintain cognitive function and quality of life?,What clinical trials are currently available that I might be eligible for?,When should we plan for changes in driving, living arrangements, and legal decision-making?,What support services and resources are available for caregivers in our area?
Common questions about NON RARE IN EUROPE: Alzheimer disease
What is NON RARE IN EUROPE: Alzheimer disease?
Alzheimer disease (also called Alzheimer's disease or AD) is the most common cause of dementia, a condition where the brain gradually loses its ability to think, remember, and carry out daily tasks. It mainly affects older adults, though early-onset forms can appear before age 65. In Alzheimer disease, abnormal proteins called amyloid plaques and tau tangles build up in the brain, damaging and eventually killing nerve cells. This leads to progressive memory loss, confusion, difficulty with language, changes in mood and personality, and trouble performing familiar activities. The disease typic
How is NON RARE IN EUROPE: Alzheimer disease inherited?
NON RARE IN EUROPE: Alzheimer disease follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does NON RARE IN EUROPE: Alzheimer disease typically begin?
Typical onset of NON RARE IN EUROPE: Alzheimer disease is late onset. Age of onset can vary across affected individuals.
Are there clinical trials for NON RARE IN EUROPE: Alzheimer disease?
Yes — 20 recruiting clinical trials are currently listed for NON RARE IN EUROPE: Alzheimer disease on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Frequently asked questions about NON RARE IN EUROPE: Alzheimer disease
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is NON RARE IN EUROPE: Alzheimer disease?
NON RARE IN EUROPE: Alzheimer disease is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:238616). It is typically inherited as multifactorial. Age of onset is generally late onset. For verified primary sources, see the UniteRare NON RARE IN EUROPE: Alzheimer disease page.
How is NON RARE IN EUROPE: Alzheimer disease inherited?
NON RARE IN EUROPE: Alzheimer disease follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for NON RARE IN EUROPE: Alzheimer disease?
Approved treatments for NON RARE IN EUROPE: Alzheimer disease are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.
Are there clinical trials recruiting for NON RARE IN EUROPE: Alzheimer disease?
UniteRare currently lists 20 clinical trials relevant to NON RARE IN EUROPE: Alzheimer disease sourced from ClinicalTrials.gov. Each trial entry includes recruitment status, eligibility criteria summary, principal-investigator information, and study locations. Patients should discuss eligibility with their healthcare provider before enrolling.
How do I find a specialist for NON RARE IN EUROPE: Alzheimer disease?
Verified NON RARE IN EUROPE: Alzheimer disease specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.
See full NON RARE IN EUROPE: Alzheimer disease page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.